World CNS Summit South Korea

Memo

Korea is rapidly emerging as a global hub for CNS innovation, with advances spanning diverse modalities, BBB shuttling technologies and differentiated targets beyond Amyloid beta and tau. As a result, pharma and venture interest has surged, with 2026 already witnessing major deals such as Fosun and AriBio, Insilico and SK Biopharmaceuticals and J and J and Prazer Therapeutics, highlighting the significant untapped potential to translate early-stage Korean assets into clinically successful, disease-modifying CNS therapies.Capitalizing on this skyrocketing investment and innovation momentum, the World CNS Summit South Korea will bring together Korean pioneers like ABL Bio, AriBio and ADEL, alongside international powerhouses including Eli Lilly, Lundbeck, JCR Pharmaceuticals and Novartis to exchange ideas and foster the collaborations needed to drive a new wave of disease-modifying neuroscience therapies.URLs:Tickets: https://go.evvnt.com/3772400-2?pid=5569Brochure: https://go.evvnt.com/3772400-3?pid=5569Date and Time: On Tuesday December 08, 2026 at 8:30 am to Thursday December 10, 2026 at 5:15 pmVenue details: Grand Hyatt Incheon, 208 Yeongjonghaeannam-ro 321beon-gil, Jung-gu, Incheon, 22382, South KoreaPrices:Drug Developer Pricing - Conference + Workshop Day: USD 2199.00,Drug Developer Pricing - Conference Only: USD 1799.00,Academic Pricing - Conference + Workshop Day: USD 1899.00,Academic Pricing - Conference Only: USD 1599.00,Service Provider Pricing - Conference + Workshop Day: USD 5149.00,Service Provider Pricing - Conference Only: USD 3849.00Speakers: Chang Hoon, Ji Executive Director, AUTOTAC Bio, Han Sungho, Founder and Chief Executive Officer, Genuv, Jae-Young Ha, Senior Vice President, AriBio, Jae-young Koh, Chief Scientific Officer, Zincure, Jeong Ho Lee, Chief Scientific Officer, Sovargen, Jin Gyu Choi, Head of Research, Mthera Pharma, Kevin Jung, Vice President, Head of Global Business Division, G2GBIO, Kwon Min-Soo, Chief Executive Officer, Brainimmunex, Seong-Wook Lee, Chief Executive Officer, Rznomics, Shawn Seong, Chief Executive Officer, Shaperon, Sungwon An, Head of Neuroscience, ABL Bio, Won-Suk Lee, Head of Business Development, ADEL, Chris Ocampo, Head of Psychiatry, Neuroscience Clinical Development, AbbVie, Lisa Li, Associate Director, Center for External Innovation, R and D, Takeda, Jiro Matsumura, Director, Regional Search and Evaluation, Novartis, Karina Krojer, Head of Asia Drug Development, Lundbeck, Mashlika Prasanth, Senior Research Officer, Neuroscience, Johnson and Johnson, Rafal Kaminski, Chief Scientific Officer, Angelini Pharma, Seoeun Lee, Senior Director, External Innovation, Eli Lilly, Shinji Kumagai, Senior Scientist, JCR Pharmaceuticals, Whitney Michiels, Vice President, Neuroscience External Innovation, Johnson and Johnson, Yuhei Ashida, Senior Scientist, JCR Pharmaceuticals, Zhaomin Chen, Former Head of Research External Innovation, Sanofi